Logo

Stratagene Licenses Gene Group IP from Kimmel Cancer Center

Apr 15, 2005

NEW YORK, April 15 (GenomeWeb News) - Stratagene today announced that it has exclusively licensed intellectual property held by the Sidney Kimmel Cancer Center of San Diego.

 

Under the terms of the agreement, Stratagene will get access to pending patents and related technology developed in the lab of Gennadi Glinsky and used to discover cancer-related genes. Stratagene will obtain exclusive rights to certain gene groups that have been shown to have predictive capabilities for cancer, particularly prostate, and breast cancers.

 

Financial terms of the agreement were not disclosed.

 

The company said it would use the IP to develop diagnostic tests based on its quantitative PCR technology.

Breaking News
The Scan

Booster Push

New data shows a decline in SARS-CoV-2 vaccine efficacy over time, which the New York Times says Pfizer is using to argue its case for a booster, even as the lower efficacy remains high.

With Help from Mr. Fluffington, PurrhD

Cats could make good study animals for genetic research, the University of Missouri's Leslie Lyons tells the Atlantic.

Man Charged With Threatening to Harm Fauci, Collins

The Hill reports that Thomas Patrick Connally, Jr., was charged with making threats against federal officials.

Nature Papers Present Approach to Find Natural Products, Method to ID Cancer Driver Mutations, More

In Nature this week: combination of cryogenic electron microscopy with genome mining helps uncover natural products, driver mutations in cancer, and more.